← Back to Search

Patient counseling for HCV associated CVD risk factors for Hepatitis C

N/A
Waitlist Available
Led By Austin T Jones, MD, PhD
Research Sponsored by Tulane University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
HCV antibody positive tested at one of six locations in New Orleans: Ozanam Inn, New Orleans Mission, Bethel Colony South, Grace House, St. Anna's Mobile Clinic, and Ruth Fertel
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up patient will be assessed for follow up within 6 months post counseling
Awards & highlights

Study Summary

This trial will compare the outcomes of patients with HCV who receive enhanced education on their condition to those who receive the standard of care. The primary outcome measure is successful linkage to hepatology for HCV treatment options and the secondary outcome is linkage to primary care for chronic disease management.

Eligible Conditions
  • Hepatitis C
  • Atherosclerosis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~patient will be assessed for follow up within 6 months post counseling
This trial's timeline: 3 weeks for screening, Varies for treatment, and patient will be assessed for follow up within 6 months post counseling for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Linkage to HCV Care
Secondary outcome measures
Linkage to Primary Care

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: CVD risk factor counselingExperimental Treatment1 Intervention
This arm will receive intervention 'Patient counseling for HCV associated CVD risk factors' in addition to standard of care Hepatitis C counseling. Cardiovascular risk factor counseling will include: Increased risk for atherosclerosis with chronic HCV infection Increased risk of heart attack and stroke Treatment of HCV infection and reduction of viral load reducing risk of stroke and heart attack
Group II: Standard of care counselingActive Control1 Intervention
This arm will receive standard of care Hepatitis C counseling: HCV infection poses an increased risk for hepatocellular carcinoma Hepatitis C is a curable disease Hepatitis C is transmitted through blood to blood contact, primarily through sharing needles HCV+ individuals should be vaccinated for Hepatitis A (HAV) and Hepatitis B (HBV) HCV+ individuals should reduce alcohol intake and shellfish consumption
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Patient counseling for HCV associated CVD risk factors
2019
N/A
~240

Find a Location

Who is running the clinical trial?

Tulane UniversityLead Sponsor
115 Previous Clinical Trials
226,271 Total Patients Enrolled
1 Trials studying Hepatitis C
341 Patients Enrolled for Hepatitis C
Austin T Jones, MD, PhDPrincipal InvestigatorTulane University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~38 spots leftby Mar 2025